| Lamivudine and adefovir combination therapy in lamivudine-resistant HBeAg-positive chronic hepatitis B patients |
|
Han Chu Lee |
|
|
| 라미부딘 내성 만성 B형 간염 환자에서 라미부딘과 아데포비어 병합요법 |
|
이한주 |
|
|
|
|
|
|
| Abstract |
|
The introduction of lamivudine (LAM) has opened a new era for the treatment of chronic hepatitis B (CHB). However, the major drawback of LAM, which currently limits its use as first-line therapy, is the high rate of occurrence of drug resistance. In patients with LAM-resistant CHB, recent long-term findings have indicated that adding adefovir (ADV) to ongoing LAM therapy was more beneficial than switching to ADV alone, because the former showed a diminished rate of resistance to ADV with a well-tolerated safety profile. Above all, the most important strategy for CHB treatment must be to use a potent first-line antiviral with high genetic barriers to resistance in order to prevent the development of multidrug resistance. |
| Key Words:
Chronic hepatitis B, Drug resistance, Lamivudine, Adefovir |
|
PDF Links
Full text via DOI
Download Citation
